RFK Jr. Removes All Members of CDC Vaccine Panel
WASHINGTON—Health Secretary Robert F. Kennedy Jr. removed all the members of a key committee that recommends vaccines, and when and how often adults and children should get them.
Kennedy wrote Monday in a Wall Street Journal opinion article that he would do a 'clean sweep' of the panel's 17 members, all of whom were appointed during the administration of former President Joe Biden.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
39 minutes ago
- Washington Post
The Latest: Pentagon says deploying Marines and National Guard to LA will cost $134 million
After persistent questioning from members of Congress on Tuesday, Defense Secretary Pete Hegseth turned to his acting comptroller, Bryn Woollacott MacDonnell, who provided the amount it would cost to send the National Guard and Marines to immigration protests in Los Angeles . She said the $134 million will come from operations and maintenance accounts.
Associated Press
41 minutes ago
- Associated Press
Gabbard says AI is speeding up intel work, including the release of the JFK assassination files
WASHINGTON (AP) — Artificial intelligence is speeding up the work of America's intelligence services, Director of National Intelligence Tulsi Gabbard said Tuesday. Speaking to a technology conference, Gabbard said AI programs, when used responsibly, can save money and free up intelligence officers to focus on gathering and analyzing information. The sometimes slow pace of intelligence work frustrated her as a member of Congress, Gabbard said, and continues to be a challenge. AI can run human resource programs, for instance, or scan sensitive documents ahead of potential declassification, Gabbard said. Her office has released tens of thousands of pages of material related to the assassinations of President John F. Kennedy and his brother, New York Sen. Robert F. Kennedy, on the orders of President Donald Trump. Experts had predicted the process could take many months or even years, but AI accelerated the work by scanning the documents to see if they contained any material that should remain classified, Gabbard said during her remarks at the Amazon Web Services Summit in Washington. 'We have been able to do that through the use of AI tools far more quickly than what was done previously — which was to have humans go through and look at every single one of these pages,' Gabbard said. The intelligence community already relies on many private-sector technologies, and Gabbard said she wants to expand that relationship instead of using federal resources to create expensive alternatives. 'How do we look at the available tools that exist — largely in the private sector — to make it so that our intelligence professionals, both collectors and analysts, are able to focus their time and energy on the things that only they can do,' she said. Gabbard, who coordinates the work of 18 intelligence agencies, has vowed to shake up America's spy services. Since assuming her role this year, she has created a new task force to consider changes to agency operations as well as greater declassification. She also has fired two veteran intelligence officers because of perceived opposition to Trump, eliminated diversity, equity and inclusion programs and relocated the staff who prepare the President's Daily Brief to give her more direct control.
Medscape
42 minutes ago
- Medscape
Fast Five Quiz: Low-Risk Myelodysplastic Syndrome
Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematopoietic stem cell disorders, each with varying levels of prognosis. Risk stratification is an important component of MDS; however, even lower-risk variants require a nuanced approach to management, and certain factors can further affect patient risk after diagnosis. What do you know about low-risk MDS? Check your knowledge with this quick quiz. Among the gene mutations identified that can influence the prognosis in MDS, SF3B1 mutation is strongly associated with favorable clinical outcomes. Other mutations such as such as TP53 , ASXL1 , EZH2 , ETV6 , and RUNX1 typically lead to poorer clinical outcomes. The National Comprehensive Care Network (NCCN) notes that combining analysis of these mutations in MDS with International Prognostic Scoring System (IPSS) can improve risk stratification beyond the strengths of the IPSS alone, which is standard practice in some treatment centers. Learn more about cytogenic studies for MDS. Data have shown that hypocellular bone marrow is one of several factors that predict good response to IST in patients with lower-risk MDS. The NCCN specifically recommends IST in select patients, generally those 'aged ≤60 years and with ≤5% marrow blasts, or those with hypocellular marrows, PNH clone positivity, or STAT-3 mutant cytotoxic T-cell clones.' Other factors associated with predicted benefit from IST include presence of dysplasia, young age (< 60 years), presence of HLA DR15, female sex, absence of ring sideroblasts, presence of trisomy 8, and relatively short duration of transfusion need. Learn more about hypocellular marrow in MDS. A study of patients with very low- and low-risk MDS found that mutations in three genes, IDH1 , IDH2 , and NPM1 , are more common among those patients with direct transformation to AML. NPM1 mutations are the most frequently-seen mutation in AML and are found in approximately 30%-35% of cases among adults. Mutations in ASXL1 , CBL , and TP53 were found to be associated with progression to higher-risk MDS but not with transformation to AML. Learn more about cytogenetics in MDS. According to a review published in JAMA , the median survival time for patients with low and very low risk MDS is 5.3 years and 8.8 years, respectively. This is consistent with other recent data. Collected data from the same JAMA review indicated that the median age for MDS diagnosis is approximately 70 years and is more common in males; chemotherapy and radiation therapy exposure are also reported significant risk factors. Further, the IPSS, revised-IPSS, and WHO classification-based prognostic scoring system are the most frequently used scoring systems for MDS risk. Learn more about MDS risk staging. Due to longer survival, patients with low-risk MDS might be given multiple red blood cell transfusions as part of their management (which could potentially lead to iron overload). To decrease iron overload, the NCCN recommends consideration of daily iron chelation with subcutaneous deferoxamine or oral deferasirox after > 20-30 transfusions. This approach is especially recommended for patients with lower-risk MDS or those who are potential candidates for transplantation. Learn more about iron chelation in MDS. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication.
